Heptares co-founder resurfaces as head of new UK drug discovery facility at Merck

22 January 2018

Merck & Co (NYSE: MRK) UK unit MSD has today announced the appointment of Dr Fiona Marshall to lead its new discovery research facility in London, focused on early bioscience discovery and entrepreneurial innovation.

Dr Marshall joins MSD from Japan’s Sosei Group (TYO Mothers Index: 4565), where she was executive vice president and chief scientific officer and, more specifically, from UK-based Heptares Therapeutics, a biotechnology company that she co-founded more than a decade ago, and which was acquired by Sosei in 2015.

According to MSD, Dr Marshall is a world renowned expert in GProtein-coupled-receptor (GPCR) biology, an active area of drug research and has more than 25 years' experience in drug discovery. She led the first group to show that GPCRs could form heterodimers and has published more than 80 peer-reviewed papers in the area of GPCRs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK